Treats CMV retinitis. ANDA 213306, held by Granules. Valganciclovir Hydrochloride.
As of Nov 16, 2026, ANDA 213306 (Valganciclovir Hydrochloride), held by Granules, was first approved by FDA on Jan 31, 2020, with 2 approved supplements and 0 published complete response letters.
Valganciclovir hydrochloride is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for: Adult Patients
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 31, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Valganciclovir Hydrochloride50MG/ML · for solution;oral | Valganciclovir Hydrochloride | Rx |
| Jun 29, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jun 29, 2022 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 31, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters